Zevra Therapeutics dissident slate wins board seats; three new directors elected

ZEVRA THERAPEUTICS, INC.

Mangless-nominated directors Bode, Calder, Watton elected; company nominees Pascoe, Posner, Tierney received 3.3M, 2.7M, and 2.5M for votes vs 14.2M, 14.8M, and 15.0M withheld.
Ratification of Ernst & Young as auditor approved with 16.3M for vs 0.3M against and 0.9M abstentions.
Mangless Proposal to repeal bylaw changes adopted after Jan 1, 2023 passed (14.5M for, 2.9M against); no such changes existed, so it had no effect.
Turnout: 50.73% of outstanding shares (17.5M of 34.5M) represented at the meeting.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

ZEVRA THERAPEUTICS, INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023 at the 2023-04-25 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-04-25

Exact text from the filing

the stockholders of the Company ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

ZEVRA THERAPEUTICS, INC. shareholders approved Election of three Class II directors to the Company’s board of directors to hold office until the 2026 annual meeting of stockholders at the 2023-04-25 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-04-25

Exact text from the filing

each of John B. Bode, Douglas W. Calder, and Corey Watton was elected as a director of the Company

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

ZEVRA THERAPEUTICS, INC. shareholders approved The Mangless Proposal to adopt a resolution that would repeal any provision of the Company’s Amended and Restated Bylaws in effect at the time of the Annual Meeting that was not included in the Company’s Amended and Restated Bylaws in effect as of January 1, 2023 (other than the change of the Compan at the 2023-04-25 meeting.

Proposal: charter amendment
Outcome: passed
Meeting: 2023-04-25

Exact text from the filing

Finally, the Mangless Proposal to adopt a resolution that would repeal any provision of the Company’s Amended and Restated Bylaws in effect at the time of the Annual Meeting that was not included in the Company’s Amended and Restated Bylaws in effect as of January 1, 2023 (other than the change of the Company’s name) was approved

View on SEC.gov

Browse all shareholder votes →

ZEVRA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-011154

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.